Hybrigenics - die neue Paion/ Epigenomics? - 500 Beiträge pro Seite

[Koenigsberg]

So jetzt starte ich einen neuen Versuch (hoffentlich fehlerfrei). Eben wurde mein Thread gelöscht, weil ich nicht korrekt zitiert hatte. Mein Fehler. Es geht um die Hybrigenics, die an der Euronext gehandelt wird. Sie ist im gleichen Segment unterwegs, wie Paion und Epi. Leider gibt es keinen deutsch- oder englischsprachigen Thread in irgendwelchen Foren. Deshalb mache ich hier mal einen auf. Wer des Französischen mächtig ist, kann sich in einen sehr intensiv diskutieren französischen Board schlau machen:

[http://www.boursorama.com/forum-hybrigenics-1rEPALHYG-1]

und vielleicht ein paar Beiträge von dort hier einbringen (natürlich in deutsch, sonst kapier ich es nicht).

Über finanznachrichten.de kommt man an folgende Pressemitteilung des Unternehmens von heute

[https://europeanequities.nyx.com/en/content/hybrigenics%E2%8…

deren Text ich gleich unten einstelle.

Kennt jemand den Laden und hat eine Meinung?

Press Release
Hybrigenics’ inecalcitol receives positive opinion from EMA
for orphan designation in chronic lymphocytic leukemia
Paris, 16 December 2013 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed on the Alternext market of Euronext Paris, with a focus on research and development of new treatments against proliferative diseases, today announces the issuance by the Committee for Orphan Medicinal Products of the European Medicines Agency (EMA) of a positive opinion for the orphan designation of inecalcitol in chronic lymphocytic leukemia (CLL), during its meeting held on December 10-12, 2013. The complete EMA Public Summary of Opinion will be available early next year.
A Phase II clinical study is currently ongoing with oral inecalcitol in CLL patients not yet eligible for chemotherapy but at high risk of progression. “This positive opinion from EMA supports our clinical development strategy of inecalcitol as an orphan drug in chronic lymphocytic leukemia, an orphan disease with high unmet medical need. We look forward to receiving the full summary report,” said Jean-François Dufour-Lamartinie, Hybrigenics’ Head of Clinical R&D.
About Chronic Lymphocytic Leukemia (CLL)
CLL is the most frequent form of leukemia (cancerous proliferative disease of circulating blood cells) and accounts for about 35% of all leukemic patients. Annual estimates of newly diagnosed CLL cases amount to close to 15,000 in the United States (American Leukemia Lymphoma Society, Facts 2012), 14,000 in Europe and 130,000 world-wide (Globocan 2008). CLL is designated as an orphan disease in the United States, Europe and Japan.
People with CLL produce too many lymphocytes (mononuclear white blood cells) of one single abnormal “family” (monoclonal) which are not fully developed (immature). Over time, these circulating CLL cells (monoclonal immature lymphocytes) in excess build up in the lymphatic system and cause large, swollen lymph nodes. They may also fill the bone marrow, reducing the number of normal white cells, red cells and platelets that can be made, thereby lowering their blood counts. There is no definitive cure for CLL.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on the Alternext market of Euronext Paris, focusing its internal R&D programs on innovative targets and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist active by oral administration. Oral inecalcitol has shown excellent tolerance and strong presumption of efficacy for the first-line treatment of metastastic castrate-resistant prostate cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes and cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance, such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein interactions for researchers in all areas of life sciences, using its ISO 9001-certified high-throughput Y2H screening platform, its sophisticated bioinformatics tools and extensive database, along with its chemical library and chemical screening platform. Hybrigenics also provides state-of-the-art genomic services specialized in DNA chips, DNA or RNA target enrichment and next generation sequencing.
2/2
Press Release
***
HYBRIGENICS is listed on the Alternext market of Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
Hybrigenics
Rémi Delansorne
CEO
Tel.: [phone]
[e-mail]
NewCap.
Financial communication
Julien Perez / Pierre Laurent
Tel.: [phone]
[e-mail]
steht folgende Pressemittelung des Unternehmens von heute

[nikodimi]

[nikodimi]

Sorry, da war ich etwas voreilig!
quelle: Hot Stocks Europe 16/12
Mehr habe ich auch nicht gefunden..

[Koenigsberg]

Geht weiter aufwärts:

Quelle: https://europeanequities.nyx.com/sites/europeanequities.nyx.…


1/2
Press Release
Hybrigenics achieves first research milestone for Servier
Paris, 20 January 2014 – Hybrigenics (ALHYG), a bio-pharmaceutical company listed
on Alternext (NYSE-Euronext) in Paris, with a focus on research and development of
new treatments for proliferative diseases, today announces the achievement of a first
drug discovery milestone in connection with the ongoing research collaboration with
Servier on ubiquitin-specific proteases (USPs) and their inhibitors. Hybrigenics has
received EUR 0.33 million in recognition of this achievement.
The research collaboration with Servier was initiated in October 2011 (see Hybrigenics’
press release of October 10, 2011). Hybrigenics provides its expertise in target
identification and validation among the numerous USPs for various therapeutic
indications. Hybrigenics also ascertains the in vitro potency and selectivity of USP
inhibitors of pharmacological interest.
“The successful achievement of this first milestone validates Hybrigenics’ cutting edge
know-how in the field of USPs and its relevance to drug discovery. We look forward to
the next steps towards a potential new drug, hand in hand with Servier’s R&D
organization,” said Remi Delansorne, Hybrigenics’ CEO.
“We are very pleased to have achieved this first milestone of collaboration
demonstrating how Hybrigenics’ technology and scientists can be a valuable
complement to our internal activities in the field of oncology,” said Dr Emmanuel Canet,
Head of Servier R&D.
About Hybrigenics
Hybrigenics (www.hybrigenics.com) is a bio-pharmaceutical company listed (ALHYG) on
Alternext (NYSE-Euronext) in Paris, focusing its internal R&D programs on innovative targets
and therapies for the treatment of proliferative cancerous or non-cancerous diseases.
Hybrigenics’ current development program is based on inecalcitol, a vitamin D receptor agonist
active by oral administration. Oral inecalcitol has shown excellent tolerance and strong
presumption of efficacy in the first-line treatment of metastastic castrate-resistant prostate
cancer in combination with Taxotere®, which is the current gold-standard chemotherapeutic
treatment for this indication. Oral inecalcitol is currently being tested in chronic lymphocytic
leukemia patients.
Hybrigenics has a research collaboration with Servier on deubiquitinating enzymes and their
inhibitors in oncology, neurology, psychiatry, rheumatology, ophthalmology, diabetes, and
cardiovascular diseases. Hybrigenics continues to build on its pioneer research position in the
field of ubiquitin-specific proteases by exploring their role in other areas of particular relevance,
such as inflammation and virology.
Hybrigenics Services (www.hybrigenics-services.com), a fully-owned subsidiary, is the market
leader in Yeast Two-Hybrid (Y2H) and related services to identify, validate and inhibit protein
interactions for researchers in all areas of life sciences, using its ISO 9001-certified highthroughput
Y2H screening platform, its sophisticated bioinformatics tools and extensive
database, along with its chemical library and chemical screening platform. Hybrigenics also
provides state-of-the-art genomic services specialized in DNA chips, DNA or RNA target
enrichment, and next generation sequencing.
Hybrigenics Corp., based in Cambridge, Mass., USA, is a fully-owned American subsidiary of
Hybrigenics.
2/2
About Servier Group
“Since the company’s creation, all of our profits are ploughed back into research” - Jacques
Servier, Founding President of the Group.
Founded in 1954, Servier is the first independent French pharmaceutical research company. Its
development is based on the continuous pursuit of innovation in the therapeutic areas of
cardiovascular, metabolic, neurologic, psychiatric, bone and joint diseases as well as cancer.
In 2012, the company recorded a turnover of 3.9 billion euros.
92% of Servier drugs are consumed internationally.
25% of turnover from Servier drugs is reinvested in Research and Development every year.
With a strong international presence in 140 countries, Servier employs more than 22 000 people
worldwide.
The Servier Group contributed 57% to the 2012 French trade surplus in the pharmaceuticals
sector.
***
HYBRIGENICS is listed on the Alternext market of Euronext Paris
ISIN: FR0004153930
Ticker: ALHYG
***
CONTACT
Servier
Communication Department
Tel. : [phone]
[e-mail]
Hybrigenics
Rémi Delansorne
CEO
Tel. : [phone]
[e-mail]
NewCap.
Financial communication
Julien Perez / Pierre Laurent
Tel. : [phone]
[e-mail]

[nikodimi]

http://www.hybrigenics.com/news/articles/view/id/111

Hybrigenics hat seinen Umsatz in 2013 um 22% gegenüber dem Vorjahr gesteigert.
Also haben wir hier eine Biotechperle, die durch ihre Service division bereits Umsätze von €6 Mio erzielt...

[nikodimi]

Also das ist doch schon mal was...orphan drug status granted...

[Koenigsberg]

Aktuell 2,15 € oder 27% plus. Nicht so schlecht.